DUBLIN--(BUSINESS WIRE)--The "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 10, 8, 12 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Report Coverage
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
- Astellas Pharma Inc
- AstraZeneca Plc
- Biogen Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cadent Therapeutics
- Coronis NeuroSciences Ltd
- Eli Lilly and Co
- F. Hoffmann-La Roche Ltd
- Heptares Therapeutics Ltd
- Intra-Cellular Therapies Inc
- Iproteos SL
- Pfizer Inc
- Sage Therapeutics Inc
- SK Biopharmaceuticals Co Ltd
- Spherium Biomed SL
- Takeda Pharmaceutical Co Ltd
- Vanda Pharmaceuticals Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8lth55/cognitive?w=4
